Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity

Supriya D. Mahajan; Ravikumar Aalinkeel; Jessica L. Reynolds; Bindukumar B. Nair; Manoj J. Mammen; Lili Dai; Paras N. Prasad; Stanley A. Schwartz

doi:10.1016/B978-0-12-801317-5.00015-3

Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity

SUNY Buffalo

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

3 Scopus citations

Abstract

Highly active antiretroviral therapy (HAART) has proven effective in reducing systemic viral loads in HIV patients but has been unable to completely eliminate the HIV from quiescent viral sequestered sites such as the brain, thus contributing to a spectrum of HIV-associated neurological disorders (HAND) defined as neuro-AIDS. Technological advances in nanoparticle design have increased their applicability in biomedical applications and show great promise for HIV therapeutics. The blood-brain barrier (BBB) is a limiting factor for the delivery of therapeutic agents into the central nervous system (CNS). BBB breakdown plays an important role in the pathogenesis of HAND. The tight junctions play a key role in the regulation of the structural and functional integrity of the BBB. No information is available on TJ modulation by nanoparticles commonly used in HIV-1 nanotherapeutics. This chapter highlights the effect of nanoparticles on BBB modulation and its implication for CNS nanotherapeutics.

Original language	English
Title of host publication	Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases
Publisher	Elsevier Inc.
Pages	251-268
Number of pages	18
ISBN (Electronic)	9780128014714
ISBN (Print)	9780128013175
DOIs	https://doi.org/10.1016/B978-0-12-801317-5.00015-3
State	Published - May 26 2015

Keywords

Antiretroviral drugs
Biodegradable nanoparticles
Blood-brain barrier
Central nervous system
HAART
HIV-1
Liposomes
Nanotherapeutics
Neuro-AIDS
Tight junctions

Access to Document

10.1016/B978-0-12-801317-5.00015-3

Cite this

Mahajan, S. D., Aalinkeel, R., Reynolds, J. L., Nair, B. B., Mammen, M. J., Dai, L., Prasad, P. N., & Schwartz, S. A. (2015). Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity. In Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases (pp. 251-268). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801317-5.00015-3

@inbook{ae92c28046a34ebaa61db3c70eed55ed,

title = "Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity",

abstract = "Highly active antiretroviral therapy (HAART) has proven effective in reducing systemic viral loads in HIV patients but has been unable to completely eliminate the HIV from quiescent viral sequestered sites such as the brain, thus contributing to a spectrum of HIV-associated neurological disorders (HAND) defined as neuro-AIDS. Technological advances in nanoparticle design have increased their applicability in biomedical applications and show great promise for HIV therapeutics. The blood-brain barrier (BBB) is a limiting factor for the delivery of therapeutic agents into the central nervous system (CNS). BBB breakdown plays an important role in the pathogenesis of HAND. The tight junctions play a key role in the regulation of the structural and functional integrity of the BBB. No information is available on TJ modulation by nanoparticles commonly used in HIV-1 nanotherapeutics. This chapter highlights the effect of nanoparticles on BBB modulation and its implication for CNS nanotherapeutics.",

keywords = "Antiretroviral drugs, Biodegradable nanoparticles, Blood-brain barrier, Central nervous system, HAART, HIV-1, Liposomes, Nanotherapeutics, Neuro-AIDS, Tight junctions",

author = "Mahajan, \{Supriya D.\} and Ravikumar Aalinkeel and Reynolds, \{Jessica L.\} and Nair, \{Bindukumar B.\} and Mammen, \{Manoj J.\} and Lili Dai and Prasad, \{Paras N.\} and Schwartz, \{Stanley A.\}",

year = "2015",

month = may,

day = "26",

doi = "10.1016/B978-0-12-801317-5.00015-3",

language = "English",

isbn = "9780128013175",

pages = "251--268",

booktitle = "Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases",

publisher = "Elsevier Inc.",

address = "United States",

}

Mahajan, SD , Aalinkeel, R , Reynolds, JL, Nair, BB, Mammen, MJ, Dai, L, Prasad, PN & Schwartz, SA 2015, Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity. in Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. Elsevier Inc., pp. 251-268. https://doi.org/10.1016/B978-0-12-801317-5.00015-3

Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity. / Mahajan, Supriya D.; Aalinkeel, Ravikumar ; Reynolds, Jessica L. et al.
Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. Elsevier Inc., 2015. p. 251-268.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Nanotherapeutic Approach to Targeting HIV-1 in the CNS

T2 - Role of Tight Junction Permeability and Blood-Brain Barrier Integrity

AU - Mahajan, Supriya D.

AU - Aalinkeel, Ravikumar

AU - Reynolds, Jessica L.

AU - Nair, Bindukumar B.

AU - Mammen, Manoj J.

AU - Dai, Lili

AU - Prasad, Paras N.

AU - Schwartz, Stanley A.

PY - 2015/5/26

Y1 - 2015/5/26

N2 - Highly active antiretroviral therapy (HAART) has proven effective in reducing systemic viral loads in HIV patients but has been unable to completely eliminate the HIV from quiescent viral sequestered sites such as the brain, thus contributing to a spectrum of HIV-associated neurological disorders (HAND) defined as neuro-AIDS. Technological advances in nanoparticle design have increased their applicability in biomedical applications and show great promise for HIV therapeutics. The blood-brain barrier (BBB) is a limiting factor for the delivery of therapeutic agents into the central nervous system (CNS). BBB breakdown plays an important role in the pathogenesis of HAND. The tight junctions play a key role in the regulation of the structural and functional integrity of the BBB. No information is available on TJ modulation by nanoparticles commonly used in HIV-1 nanotherapeutics. This chapter highlights the effect of nanoparticles on BBB modulation and its implication for CNS nanotherapeutics.

AB - Highly active antiretroviral therapy (HAART) has proven effective in reducing systemic viral loads in HIV patients but has been unable to completely eliminate the HIV from quiescent viral sequestered sites such as the brain, thus contributing to a spectrum of HIV-associated neurological disorders (HAND) defined as neuro-AIDS. Technological advances in nanoparticle design have increased their applicability in biomedical applications and show great promise for HIV therapeutics. The blood-brain barrier (BBB) is a limiting factor for the delivery of therapeutic agents into the central nervous system (CNS). BBB breakdown plays an important role in the pathogenesis of HAND. The tight junctions play a key role in the regulation of the structural and functional integrity of the BBB. No information is available on TJ modulation by nanoparticles commonly used in HIV-1 nanotherapeutics. This chapter highlights the effect of nanoparticles on BBB modulation and its implication for CNS nanotherapeutics.

KW - Antiretroviral drugs

KW - Biodegradable nanoparticles

KW - Blood-brain barrier

KW - Central nervous system

KW - HAART

KW - HIV-1

KW - Liposomes

KW - Nanotherapeutics

KW - Neuro-AIDS

KW - Tight junctions

UR - https://www.scopus.com/pages/publications/85054288240

U2 - 10.1016/B978-0-12-801317-5.00015-3

DO - 10.1016/B978-0-12-801317-5.00015-3

M3 - Chapter

AN - SCOPUS:85054288240

SN - 9780128013175

SP - 251

EP - 268

BT - Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases

PB - Elsevier Inc.

ER -

Nanotherapeutic Approach to Targeting HIV-1 in the CNS: Role of Tight Junction Permeability and Blood-Brain Barrier Integrity

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this